IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma

KIZ OpenIR > 科研部门 > 疾病机理遗传学和进化医学学科组（姚永刚）

	IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma; IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma; IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma; IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma; IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma; IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma
	Lu J 1; Zou Y 2; Xu L2,3 ; Yang RX 4; Fan Y 2,3; Zhang W 2; Yu DD2; Yao YG*2 ; yudandan@mail.kiz.ac.cn
	2014 ; 2014 ; 2014 ; 2014 ; 2014 ; 2014
发表期刊	MEDICAL SCIENCE MONITOR ; MEDICAL SCIENCE MONITOR ; MEDICAL SCIENCE MONITOR ; MEDICAL SCIENCE MONITOR ; MEDICAL SCIENCE MONITOR ; MEDICAL SCIENCE MONITOR
卷号	20 期号:X 页码:247-254
合作性质	其它 ; 其它 ; 其它 ; 其它 ; 其它 ; 其它
摘要	Background: Recent studies have identified prevalent isocitrate dehydrogenase 1 (IDH1) codon 132 mutations (p.R132) in gliomas and acute myeloid leukemia (AML). The IDH1 mutations lead to a loss of its normal enzymatic activity and acquisition of neomorphic activity in production of alpha-ketoglutarate (alpha-KG) and 2-hydroxyglutarate (2-HG), which finally cause alterations of multiple gene expression of tumorigenesis-associated alpha-KG-dependent enzymes. The aim of this study was to determine whether IDH1 p.R132 mutations are involved in the carcinogenesis of hepatocellular carcinoma. Material/Methods: A total of 87 Han Chinese patients with primary hepatocellular carcinoma (HCC) were analyzed by direct DNA sequencing for IDH1 p.R132 mutations. The expression levels of multiple alpha-KG-dependent enzymes and associated genes were quantified in HepG2 cells overexpressing IDH1 p.R132 mutants by Western blotting and real-time PCR. Results: None of 87 Han Chinese patients with HCC harbored any IDH1 p.R132 mutations. The protein levels of HIF-1 alpha and histone methylation marker (H3K4me3 and H3K79me2) were determined in HepG2 cells overexpressing IDH1 p.R132 mutants, but we discerned no difference. Measurement of mRNA expression levels of VEGF, GLUT1, and HOXA genes also showed no significant difference between cells overexpressing IDH1 wild-type and p.R132 mutants. Conclusions: Our negative results, together with some previous reports of the absence of IDH1 p.R132 mutations in HCC tissues, suggests that IDH1 p.R132 mutations are not actively involved in the development of HCC.; Background: Recent studies have identified prevalent isocitrate dehydrogenase 1 (IDH1) codon 132 mutations (p.R132) in gliomas and acute myeloid leukemia (AML). The IDH1 mutations lead to a loss of its normal enzymatic activity and acquisition of neomorphic activity in production of alpha-ketoglutarate (alpha-KG) and 2-hydroxyglutarate (2-HG), which finally cause alterations of multiple gene expression of tumorigenesis-associated alpha-KG-dependent enzymes. The aim of this study was to determine whether IDH1 p.R132 mutations are involved in the carcinogenesis of hepatocellular carcinoma. Material/Methods: A total of 87 Han Chinese patients with primary hepatocellular carcinoma (HCC) were analyzed by direct DNA sequencing for IDH1 p.R132 mutations. The expression levels of multiple alpha-KG-dependent enzymes and associated genes were quantified in HepG2 cells overexpressing IDH1 p.R132 mutants by Western blotting and real-time PCR. Results: None of 87 Han Chinese patients with HCC harbored any IDH1 p.R132 mutations. The protein levels of HIF-1 alpha and histone methylation marker (H3K4me3 and H3K79me2) were determined in HepG2 cells overexpressing IDH1 p.R132 mutants, but we discerned no difference. Measurement of mRNA expression levels of VEGF, GLUT1, and HOXA genes also showed no significant difference between cells overexpressing IDH1 wild-type and p.R132 mutants. Conclusions: Our negative results, together with some previous reports of the absence of IDH1 p.R132 mutations in HCC tissues, suggests that IDH1 p.R132 mutations are not actively involved in the development of HCC.; Background: Recent studies have identified prevalent isocitrate dehydrogenase 1 (IDH1) codon 132 mutations (p.R132) in gliomas and acute myeloid leukemia (AML). The IDH1 mutations lead to a loss of its normal enzymatic activity and acquisition of neomorphic activity in production of alpha-ketoglutarate (alpha-KG) and 2-hydroxyglutarate (2-HG), which finally cause alterations of multiple gene expression of tumorigenesis-associated alpha-KG-dependent enzymes. The aim of this study was to determine whether IDH1 p.R132 mutations are involved in the carcinogenesis of hepatocellular carcinoma. Material/Methods: A total of 87 Han Chinese patients with primary hepatocellular carcinoma (HCC) were analyzed by direct DNA sequencing for IDH1 p.R132 mutations. The expression levels of multiple alpha-KG-dependent enzymes and associated genes were quantified in HepG2 cells overexpressing IDH1 p.R132 mutants by Western blotting and real-time PCR. Results: None of 87 Han Chinese patients with HCC harbored any IDH1 p.R132 mutations. The protein levels of HIF-1 alpha and histone methylation marker (H3K4me3 and H3K79me2) were determined in HepG2 cells overexpressing IDH1 p.R132 mutants, but we discerned no difference. Measurement of mRNA expression levels of VEGF, GLUT1, and HOXA genes also showed no significant difference between cells overexpressing IDH1 wild-type and p.R132 mutants. Conclusions: Our negative results, together with some previous reports of the absence of IDH1 p.R132 mutations in HCC tissues, suggests that IDH1 p.R132 mutations are not actively involved in the development of HCC.; Background: Recent studies have identified prevalent isocitrate dehydrogenase 1 (IDH1) codon 132 mutations (p.R132) in gliomas and acute myeloid leukemia (AML). The IDH1 mutations lead to a loss of its normal enzymatic activity and acquisition of neomorphic activity in production of alpha-ketoglutarate (alpha-KG) and 2-hydroxyglutarate (2-HG), which finally cause alterations of multiple gene expression of tumorigenesis-associated alpha-KG-dependent enzymes. The aim of this study was to determine whether IDH1 p.R132 mutations are involved in the carcinogenesis of hepatocellular carcinoma. Material/Methods: A total of 87 Han Chinese patients with primary hepatocellular carcinoma (HCC) were analyzed by direct DNA sequencing for IDH1 p.R132 mutations. The expression levels of multiple alpha-KG-dependent enzymes and associated genes were quantified in HepG2 cells overexpressing IDH1 p.R132 mutants by Western blotting and real-time PCR. Results: None of 87 Han Chinese patients with HCC harbored any IDH1 p.R132 mutations. The protein levels of HIF-1 alpha and histone methylation marker (H3K4me3 and H3K79me2) were determined in HepG2 cells overexpressing IDH1 p.R132 mutants, but we discerned no difference. Measurement of mRNA expression levels of VEGF, GLUT1, and HOXA genes also showed no significant difference between cells overexpressing IDH1 wild-type and p.R132 mutants. Conclusions: Our negative results, together with some previous reports of the absence of IDH1 p.R132 mutations in HCC tissues, suggests that IDH1 p.R132 mutations are not actively involved in the development of HCC.; Background: Recent studies have identified prevalent isocitrate dehydrogenase 1 (IDH1) codon 132 mutations (p.R132) in gliomas and acute myeloid leukemia (AML). The IDH1 mutations lead to a loss of its normal enzymatic activity and acquisition of neomorphic activity in production of alpha-ketoglutarate (alpha-KG) and 2-hydroxyglutarate (2-HG), which finally cause alterations of multiple gene expression of tumorigenesis-associated alpha-KG-dependent enzymes. The aim of this study was to determine whether IDH1 p.R132 mutations are involved in the carcinogenesis of hepatocellular carcinoma. Material/Methods: A total of 87 Han Chinese patients with primary hepatocellular carcinoma (HCC) were analyzed by direct DNA sequencing for IDH1 p.R132 mutations. The expression levels of multiple alpha-KG-dependent enzymes and associated genes were quantified in HepG2 cells overexpressing IDH1 p.R132 mutants by Western blotting and real-time PCR. Results: None of 87 Han Chinese patients with HCC harbored any IDH1 p.R132 mutations. The protein levels of HIF-1 alpha and histone methylation marker (H3K4me3 and H3K79me2) were determined in HepG2 cells overexpressing IDH1 p.R132 mutants, but we discerned no difference. Measurement of mRNA expression levels of VEGF, GLUT1, and HOXA genes also showed no significant difference between cells overexpressing IDH1 wild-type and p.R132 mutants. Conclusions: Our negative results, together with some previous reports of the absence of IDH1 p.R132 mutations in HCC tissues, suggests that IDH1 p.R132 mutations are not actively involved in the development of HCC.; Background: Recent studies have identified prevalent isocitrate dehydrogenase 1 (IDH1) codon 132 mutations (p.R132) in gliomas and acute myeloid leukemia (AML). The IDH1 mutations lead to a loss of its normal enzymatic activity and acquisition of neomorphic activity in production of alpha-ketoglutarate (alpha-KG) and 2-hydroxyglutarate (2-HG), which finally cause alterations of multiple gene expression of tumorigenesis-associated alpha-KG-dependent enzymes. The aim of this study was to determine whether IDH1 p.R132 mutations are involved in the carcinogenesis of hepatocellular carcinoma. Material/Methods: A total of 87 Han Chinese patients with primary hepatocellular carcinoma (HCC) were analyzed by direct DNA sequencing for IDH1 p.R132 mutations. The expression levels of multiple alpha-KG-dependent enzymes and associated genes were quantified in HepG2 cells overexpressing IDH1 p.R132 mutants by Western blotting and real-time PCR. Results: None of 87 Han Chinese patients with HCC harbored any IDH1 p.R132 mutations. The protein levels of HIF-1 alpha and histone methylation marker (H3K4me3 and H3K79me2) were determined in HepG2 cells overexpressing IDH1 p.R132 mutants, but we discerned no difference. Measurement of mRNA expression levels of VEGF, GLUT1, and HOXA genes also showed no significant difference between cells overexpressing IDH1 wild-type and p.R132 mutants. Conclusions: Our negative results, together with some previous reports of the absence of IDH1 p.R132 mutations in HCC tissues, suggests that IDH1 p.R132 mutations are not actively involved in the development of HCC.
关键词	Mutation - Genetics Mutation - Genetics Mutation - Genetics Mutation - Genetics Mutation - Genetics Mutation - Genetics Carcinogenesis Carcinogenesis Carcinogenesis Carcinogenesis Carcinogenesis Carcinogenesis Histones Histones Histones Histones Histones Histones Carcinoma Carcinoma Carcinoma Carcinoma Carcinoma Carcinoma Hepatocellular Hepatocellular Hepatocellular Hepatocellular Hepatocellular Hepatocellular
收录类别	SCI ; SCI ; SCI ; SCI ; SCI ; SCI
WOS记录号	WOS:000331659600001 ; WOS:000331659600001 ; WOS:000331659600001 ; WOS:000331659600001 ; WOS:000331659600001 ; WOS:000331659600001
引用统计
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/152453/8074
专题	科研部门_疾病机理遗传学和进化医学学科组（姚永刚）科研部门_动物模型与人类重大疾病机理重点实验室
通讯作者	yudandan@mail.kiz.ac.cn
作者单位	1.Hepatology and Cancer Biotherapy Ward, Beijing YouAn Hospital, Capital Medical University, Beijing, China 2.Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology, Kunming, Yunnan, China 3.Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming, Yunnan, China 4.Third Affiliated Hospital of Kunming Medical University (Tumor Hospital of Yunnan Province), Kunming, Yunnan, China
推荐引用方式 GB/T 7714	Lu J,Zou Y,Xu L,et al. IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma, IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma, IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma, IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma, IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma, IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma[J]. MEDICAL SCIENCE MONITOR, MEDICAL SCIENCE MONITOR, MEDICAL SCIENCE MONITOR, MEDICAL SCIENCE MONITOR, MEDICAL SCIENCE MONITOR, MEDICAL SCIENCE MONITOR,2014, 2014, 2014, 2014, 2014, 2014,20, 20, 20, 20, 20, 20(X):247-254, 247-254, 247-254, 247-254, 247-254, 247-254.
APA	Lu J.,Zou Y.,Xu L.,Yang RX.,Fan Y.,...&yudandan@mail.kiz.ac.cn.(2014).IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma.MEDICAL SCIENCE MONITOR,20(X),247-254.
MLA	Lu J,et al."IDH1 p.R132 mutations may not be actively involved in the carcinogenesis of hepatocellular carcinoma".MEDICAL SCIENCE MONITOR 20.X(2014):247-254.

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
2014101303.pdf（823KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文